Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1616-1628

  Saito, Ken ^a   Takigawa, Nagio ^d   Ohtani, Naoko ^f   Iioka, Hidekazu ^a,g   Tomita, Yuki ^a,b   Ueda, Ryuzo ^h   Fukuoka, Junya ⁱ   Kuwahara, Kazuhiko ^j   Ichihara, Eiki ^e   Kiura, Katsuyuki ^f   Kondo, Eisaku ^a,c  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^f CANCER INSTITUTE   (Japan)

^g Advanced Medical Research Center   (Japan)

^h AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ TOYAMA UNIVERSITY HOSPITAL   (Japan)

^j KUMAMOTO UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GEFITINIB; MESSENGER RNA; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PEPTIDE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CLONE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; ENZYME ACTIVATION; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PEPTIDE SYNTHESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG RESISTANCE; GENETICS; INTRACELLULAR SPACE; LUNG TUMOR; METABOLISM; MOLECULAR GENETICS; MUTATION; NON SMALL CELL LUNG CANCER; PROTEIN TRANSPORT; TUMOR CELL LINE; DRUG ANTAGONISM;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; INTRACELLULAR SPACE; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDES; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 84882269037     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1239     Document Type: Article

References (39)

1. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287:1969-73.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
4. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101: 13306-311.
5. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12: 3908-14.
6. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 2004;305:1163-7.
7. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinibsensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005;102:3788-93.
8. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006;116:2695-706.
9. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
10. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:5764-9.
11. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105: 2070-5.
12. Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ 2nd, et al. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 2007;67:7319-26.
13. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11:217-27.
14. Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, Griffin JD. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 2005; 65:8968-74.
15. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004;64:7241-4.
16. Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 2007;67:5667-72.
17. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, et al. A novel p16INK4A transcript. Cancer Res 1995;55:2995-7.
18. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
19. Xi L, Feber A, Gupta V, Wu M, Bergemann AD, Landreneau RJ, et al. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res 2008;36:6535-47.
20. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 2000;60:129-33.
21. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366: 704-7.
22. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998;12:2984-91.
23. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
24. Ogino A, Kitao H, Hirano S, Uchida A, Ishiai M, Kozuki T, et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res 2007;67:7807-14.
25. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66:5542-8.
26. Maruyama M, Kobayashi N, Westerman KA, Sakaguchi M, Allain JE, Totsugawa T, et al. Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT. Transplantation 2004;77:446-51.
27. Matsumura T, Takesue M, Westerman KA, Okitsu T, Sakaguchi M, Fukazawa T, et al. Establishment of an immortalized human-liver endothelial cell line with SV40T and hTERT. Transplantation 2004; 77:1357-65.
28. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in nonsmall cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276-82.
29. Miyazawa H, Tanaka T, Nagai Y, Matsuoka M, Hugun, Sutani A, et al. Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci 2008;99:595-600.
30. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008;132:487-98.
31. Mizuarai S, Yamanaka K, Kotani H. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res 2006;66: 6319-26.
32. Heerdt BG, Houston MA, Anthony GM, Augenlicht LH. Mitochondrial membrane potential (delta psi(mt)) in the coordination of p53-independent proliferation and apoptosis pathways in human colonic carcinoma cells. Cancer Res 1998;58:2869-75.
33. Kondo E, Tanaka T, Miyake T, Ichikawa T, Hirai M, Adachi M, et al. Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines. Mol Cancer Ther 2008;7:1461-71.
34. Irvine M, Philipsz S, Frausto M, Mijatov B, Gallagher SJ, Fung C, et al. Amino terminal hydrophobic import signals target the p14(ARF) tumor suppressor to the mitochondria. Cell Cycle 2010;9:829-39.
35. Zheleva DI, McInnes C, Gavine AL, Zhelev NZ, Fischer PM, Lane DP. Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin A. J Pept Res 2002;60:257-70.
36. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8:808-15.
37. Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003;12: 1151-64.
38. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004;24:985-96.
39. Kondo E, Seto M, Yoshikawa K, Yoshino T. Highly efficient delivery of p16 antitumor peptide into aggressive leukemia/lymphoma cells using a novel transporter system. Mol Cancer Ther 2004;3:1623-30.